FimmCyte and Richter Collaborate on Endometriosis Breakthrough – Startupticker.ch
Startupticker.ch shared a post on LinkedIn։
“FimmCyte, a femtech company developing new treatments for endometriosis, has entered into a research collaboration and option-to-license agreement with Richter, a leading Hungarian pharmaceutical company, to advance research on its lead clinical candidate, FMC2. The parties have fully negotiated a definitive, exclusive and worldwide license agreement for the future development and commercialization of the antibody. FimmCyte will be eligible to receive development and commercial milestone payments, together with tiered royalties on net sales, as provided under the pre-agreed license agreement.
More about FimmCyte, its clinical candidate and the collaboration in our article․”
Stay updated on all scientific advances in the field of fertility with Fertility News.
-
Apr 17, 2026, 04:19WHO Raises Alarm Over Global Burden of Child Marriage
-
Apr 17, 2026, 04:11Sign Up for Our Latest BFS Insights Webinar – British Fertility Society
-
Apr 17, 2026, 03:43Chantelle Pereira: Endometriosis Paper Highlights Diagnostic Delays and Gaps in Patient Care
-
Apr 17, 2026, 03:35Tal Varsano: Plasma Proteomic Signature of the Human Menstrual Cycle
-
Apr 17, 2026, 03:30Vacancy for a Friendly Senior Embryologist in Berlin, Germany – ESHRE
-
Apr 17, 2026, 03:05Clinical Study Supports Continued IVF After Unsuccessful First Transfer – RBMO
-
Apr 17, 2026, 02:57Standing Together for Black Maternal Health Week – ACOG
-
Apr 16, 2026, 17:24No Difference Between Natural and Artificial Cycles in Endometrium Cases – RBMO
-
Apr 16, 2026, 17:20Marco Zaccaria: Recognizing Innovation in Adenomyosis Treatment